Related references
Note: Only part of the references are listed.Cancer Patients: Implications for Adjuvant Therapies Stratification of Intermediate-risk Non-muscle-invasive Bladder
Francesco Soria et al.
EUROPEAN UROLOGY FOCUS (2021)
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage
Dominic C. Grimberg et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)
Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them
George E. Koch et al.
UROLOGY (2021)
Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response
Patrick J. Hensley et al.
BJU INTERNATIONAL (2021)
Update on the guideline of guidelines: non-muscle-invasive bladder cancer
Jacob Taylor et al.
BJU INTERNATIONAL (2020)
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
Ryan L. Steinberg et al.
JOURNAL OF UROLOGY (2020)
Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer
Niranjan J. Sathianathen et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis
Jun-Lin Lu et al.
CANCER MEDICINE (2020)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what
Charles C. Peyton et al.
WORLD JOURNAL OF UROLOGY (2019)
Device-assisted intravesical therapy for non-muscle invasive bladder cancer
Kees Hendricksen
TRANSLATIONAL ANDROLOGY AND UROLOGY (2019)
Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
Nathalie van den Tempel et al.
PLOS ONE (2018)
Clinical Associations of Early Dysnatremias in Critically Ill Neonates and Infants Undergoing Cardiac Surgery
Jon Kaufman et al.
PEDIATRIC CARDIOLOGY (2017)
Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients
Ho Kyung Seo et al.
ONCOTARGET (2017)
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2016)
Sodium bicarbonate use and the risk of hypernatremia in thoracic aortic surgical patients with metabolic acidosis following deep hypothermic circulatory arrest
Kamrouz Ghadimi et al.
ANNALS OF CARDIAC ANAESTHESIA (2016)
Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial
Robert S. Svatek et al.
CLINICAL CANCER RESEARCH (2015)
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS)
J. Alfred Witjes et al.
BJU INTERNATIONAL (2013)
Urinary pH Is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor
Takahiro Maeda et al.
JOURNAL OF UROLOGY (2011)
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
Seth P. Lerner et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: A prospective randomized study
N Sakamoto et al.
INTERNATIONAL JOURNAL OF UROLOGY (2001)
Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial
JLS Au et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
